A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection
Funder: SYNAIRGEN RESEARCH LIMITED
Sponsor: SYNAIRGEN RESEARCH LIMITED
Approval Date: 30 March 2020
SNG001 is an inhaled form (one that is breathed in through the nose) of interferon beta-1a (a drug used to treat multiple sclerosis). It contains a protein (interferon beta) which is made in the lungs during viral lung infections and which stops the growth of viruses. It has already been tested by a company called Synairgen in patients with chronic obstructive pulmonary disease (a type of lung disease causing long-term breathing problems). The purpose of this study is to confirm that SNG001 can prevent or reduce the worsening of lower respiratory tract illness (infection of the lungs) in patients with the SARS-CoV-2 virus (the virus that causes COVID-19). The drug's safety and effectiveness will both be assessed. The study will include patients with COVID-19 infection who are at high risk (e.g. elderly or diabetics) whether in hospital or not. They will receive either SNG001 or placebo (treatment with no active ingredient) inhaled once daily for 14 days. Their general medical condition, levels of breathlessness, cough and sputum (mucus from the lungs) will be recorded every day, along with any safety information.
The purpose of this study is to confirm that SNG001 can prevent/limit the worsening of LRT illness in the context of SARS-CoV-2. Safety and efficacy will be assessed.
Study URL:Back to listing